Beta Bionics, Inc.
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Error: Invalid Earnings JSON format.
Earnings estimate
| Number of analysts | — | — | — | — |
|---|---|---|---|---|
| Average estimate | — | — | — | — |
| Low estimate | — | — | — | — |
| High estimate | — | — | — | — |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr.
—
Current year
—
Next year
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total reported revenue | 12.00M | 179,000 |
| Cost of revenue | 5.69M | — |
| Gross profit | 6.31M | 179,000 |
| Operating expense | ||
| Research & development | 17.94M | 31.43M |
| Selling general and admin | 24.22M | 34.60M |
| Other operating expenses | — | — |
| Operating income | -35.85M | -65.84M |
| Non operating interest income | ||
| Income | 1.78M | 196,000 |
| Expense | 68,000 | 14,000 |
| Other income expense | -9.96M | 911,000 |
| Pretax income | -44.10M | -64.75M |
| Tax provision | — | — |
| Net income | -44.10M | -64.75M |
| Basic EPS | — | — |
| Diluted EPS | — | — |
| Basic average shares | — | — |
| Diluted average shares | — | — |
| EBITDA | -31.98M | -63.56M |
| Net income from continuing op. | -44.10M | -64.75M |
| Minority interests | — | — |
| Preferred stock dividends | — | — |
Balance sheet
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total assets | 110.04M | 35.53M |
| Current assets | ||
| Cash | — | — |
| Cash equivalents | — | — |
| Cash and cash equivalents | 26.57M | 27.68M |
| Other short term investments | 70.18M | — |
| Accounts receivable | 4.45M | — |
| Other receivables | — | — |
| Inventory | 1.25M | — |
| Prepaid assets | 908,000 | 542,000 |
| Restricted cash | — | — |
| Assets held for sale | — | — |
| Hedging assets | — | — |
| Other current assets | 275,000 | 250,000 |
| Non current assets | ||
| Properties | 8.11M | 7.56M |
| Land and improvements | — | — |
| Machinery furniture equipment | 1.39M | 1.55M |
| Construction in progress | 167,000 | 182,000 |
| Leases | 951,000 | 951,000 |
| Accumulated depreciation | -4.42M | -3.37M |
| Goodwill | — | — |
| Investment properties | — | — |
| Financial assets | — | — |
| Intangible assets | — | — |
| Investments and advances | — | — |
| Other non current assets | 221,000 | 193,000 |
| Total liabilities | 313.15M | 205.56M |
| Current liabilities | ||
| Accounts payable | 1.17M | 430,000 |
| Accrued expenses | 2.19M | 762,000 |
| Short term debt | 1.22M | 976,000 |
| Deferred revenue | 87,000 | — |
| Tax payable | — | — |
| Pensions | 5.48M | 5.38M |
| Other current liabilities | 462,000 | 184,000 |
| Non current liabilities | ||
| Long term debt | 3.00M | 3.16M |
| Provision for risks and charges | — | — |
| Deferred liabilities | — | — |
| Derivative product liabilities | 37.57M | 10.50M |
| Other non current liabilities | — | — |
| Shareholders equity | ||
| Common stock | 1,000 | 1,000 |
| Retained earnings | -229.66M | -185.57M |
| Other shareholders equity | 137,000 | — |
| Total shareholders equity | -203.11M | -170.03M |
| Additional paid in capital | 26.42M | 15.53M |
| Treasury stock | — | — |
| Minority interest | — | — |
Cash flow statement
| 2023 | 2022 | |
|---|---|---|
| Operating Activities | ||
| Net Income | -44.10M | -64.75M |
| Depreciation | 2.09M | 2.09M |
| Deferred Taxes | — | — |
| Stock-Based Compensation | 5.66M | 6.10M |
| Other Non-Cash Items | — | 14,000 |
| Accounts Receivable | -4.49M | — |
| Accounts Payable | 716,000 | -77,000 |
| Other Assets & Liabilities | -1.82M | -825,000 |
| Operating Cash Flow | -41.95M | -57.45M |
| Investing Activities | ||
| Capital Expenditures | -398,000 | -769,000 |
| Net Intangibles | — | — |
| Net Acquisitions | — | — |
| Purchase of Investments | -69.30M | — |
| Sale of Investments | — | — |
| Investing Cash Flow | -69.69M | -769,000 |
| Financing Activities | ||
| Long-Term Debt Issuance | — | — |
| Long-Term Debt Payments | — | — |
| Other Financing Charges | — | — |
| Financing Cash Flow | 101.00M | 56.39M |
| Other Cash Details | ||
| End Cash Position | 26.67M | 27.78M |
| Income Tax Paid | — | — |
| Interest Paid | — | — |
| Free Cash Flow | -32.85M | -60.98M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|
Article
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted.
Feb 9, 2025
Article
Beta Bionics: A Sugar Rush For This IPO
Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years.
Feb 2, 2025
Article
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
Feb 1, 2025
